MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jconrel.2020.05.036

Медицинская библиотека · Journal of controlled release : official journal of the Controlled Release Society · 2020

Development of a long acting FGF21 analogue-albumin fusion protein and its anti-diabetic effects.

Watanabe Hiroshi, Miyahisa Masako, Chikamatsu Mayuko, Nishida Kento, Minayoshi Yuki, Takano Mei, Ichimizu Shota, Kobashigawa Yoshihiro, Morioka Hiroshi, Maeda Hitoshi, Maruyama Toru

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Fibroblast growth factor 21 (FGF21) is a hormone-like protein that improves blood glucose and lipid metabolism. However, its short half-life and instability are bottlenecks to its clinical applications. In this study, to extend its pharmacological action, we created a stabilized mutant FGF21 (mFGF21:ΔHPIP, P171G, A180E, L118C-A134C, S167A) and then genetically fused it with human albumin (HSA-mFGF21) via a polypeptide linker. Physicochemical analyses suggested that HSA-mFGF21 was formed from both intact HSA and mFGF21. Pharmacokinetic findings indicated the half-life of HSA-mFGF21 was 20 times longer than that of FGF21. In addition, HSA-mFGF21 was persistently distributed in adipose tissue as a target tissue. The in vivo hypoglycemic activity of HSA-mFGF21 using streptozotocin (STZ)-induced type I diabetes model mice, in which insulin secretion was suppressed, showed that a single intravenous administration of HSA-mFGF21 rapidly alleviated hyperglycemia. At that time, HSA-mFGF21 increased GLUT1 mRNA expression in adipose tissue without having any effect on insulin secretion. A twice weekly administration of HSA-mFGF21 continuously suppressed blood glucose levels and ameliorated the abnormalities of adipose tissue induced by STZ treatment. Interestingly, HSA-mFGF21 showed no hypoglycemic effects in healthy mice. Together, HSA-mFGF21 could be a novel biotherapeutic for the treatment of metabolic disorders including diabetes mellitus.

Для цитирования: Watanabe Hiroshi, Miyahisa Masako, Chikamatsu Mayuko, Nishida Kento, Minayoshi Yuki, Takano Mei, Ichimizu Shota, Kobashigawa Yoshihiro, Morioka Hiroshi, Maeda Hitoshi, Maruyama Toru. Development of a long acting FGF21 analogue-albumin fusion protein and its anti-diabetic effects.. Journal of controlled release : official journal of the Controlled Release Society. 2020. DOI: 10.1016/j.jconrel.2020.05.036.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.